Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aurinia Pharmaceuticals Inc AUPH

Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.


NDAQ:AUPH - Post by User

Bullboard Posts
Comment by Moneyday0on Aug 16, 2016 12:21pm
147 Views
Post# 25146349

RE:RE;RE;...GOOD FOR YOU , HOPE YOU HAVE ENOUGH CASH UP UR A**

RE:RE;RE;...GOOD FOR YOU , HOPE YOU HAVE ENOUGH CASH UP UR A**Your in the money - were really in the money before yesterday and looks like good recovery on FACTs not headline mis-reps of yesterday. Guess your sold now are trying to get back in cheap - why on earth would you stay with such a stock given your prognosis, discontent and disbelief in voclosporin and mngt and everything else you site supporting your thesis this is a corrupt stock. Why bother posting? New CEO now with incredible merits, expert docs in the field onboard, real results that show voclosporin makes a difference in the life of LN diagnosed PEOPLE that are hurting. Now your stating the FDA does not support voclosporin... how could they do phase 2b and put people at risk if FDA condemned the product!!!!!! Stock price and smart people are buying up the stock today and volume is approaching yesterdays initial panic sell off. Level heads are reviewing results and making factual decisions not guess work. If FDA and results suggested something drastically wrong, it be selling off today at $.50 and volume would be 15 to 20 million shares. But obviously you have been here longer and know more than the rest of us so good luck to ya whatever your action plan is. Certainly no time to be shorting but keep trying if you wish.
Bullboard Posts